Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies

• Published in: Cytotherapy (Oxford, England) Vol. 24; no. 10; pp. 979 - 989
• Main Authors: Bastin, Donald J., Quizi, Jennifer, Kennedy, Michael A., Kekre, Natasha, Auer, Rebecca C.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01-10-2022
• Subjects: autologous whole cell vaccine; cell therapy; cryopreservation; culture conditions; hematological cancer; manufacture; manufacture; hematological cancer; autologous whole cell vaccine; culture conditions; cell therapy; cryopreservation
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2022.03.010

Autologous whole cell vaccines use a patient's own tumor cells as a source of antigen to elicit an anti-tumor immune response in vivo. Recently, the authors conducted a systematic review of clinical trials employing these products in hematological cancers that showed a favorable safety profile and trend toward efficacy. However, it was noted that manufacturing challenges limit both the efficacy and clinical implementation of these vaccine products. In the current literature review, the authors sought to define the issues surrounding the manufacture of autologous whole cell products for hematological cancers. The authors describe key factors, including the acquisition, culture, cryopreservation and transduction of malignant cells, that require optimization for further advancement of the field. Furthermore, the authors provide a summary of pre-clinical work that informs how the identified challenges may be overcome. The authors also highlight areas in which future basic research would be of benefit to the field. The goal of this review is to provide a roadmap for investigators seeking to advance the field of autologous cell vaccines as it applies to hematological malignancies.